Today’s science involves less white lab coats and observations jotted into notebooks and more automated laboratory systems generating millions – if not billions – of data points that are then studied via a computer screen. Moreover, today’s data is no longer just observational – it is numeric, and compiled from multiple disciplines like sequencing, mass spectrometry, and other high-throughput techniques.
While these novel data generation technologies have transformed our ability to study biology, they also create a new challenge. Extracting meaningful insights from millions of data points to improve our understanding of disease, accelerate drug development and ultimately benefit patients is now harder and more time-consuming than ever.
VUGENE’s mission is to free the teams doing globally important work from automatable tasks, allowing them to put their minds to where they can be most useful in advancing science. Beyond saving time, VUGENE’s bespoke analyses can uncover hidden relationships across biological datasets, revealing unique mechanistic insights and potential therapeutic opportunities that might otherwise remain hidden.
Demystifying metabolites with biocrates
Metabolomics is a powerful but complex field, often presenting a high barrier to entry due to the scale and intricacy of the data involved. As a result, research teams can struggle to fully integrate metabolite information into multi-omics studies, limiting its potential impact in vital fields such as diagnostics and drug development.
biocrates, an Austria-based biotech, aims to democratize access to metabolomics by providing both the expertise and mass spectrometry kit needed to generate high-quality metabolite data. To unlock even greater value, in 2024 biocrates partnered with VUGENE to integrate multi-omics analysis service with their existing metabolomics expertise aiming to reveal meaningful relationships and systems-level insights.
Finding early Alzheimer’s biomarkers with Corewell Health
Alzheimer’s disease is one of the leading causes of death globally, with tens of millions of people expected to be affected in the coming years. While extensive research is underway to develop new treatments, identifying the right patients for clinical trials remains a major bottleneck, as strict inclusion criteria make recruitment both complex and costly.
The Corewell Health Research Institute is working to address this by studying disease mechanisms and identifying biomarkers that can improve patient stratification and allow for more effective clinical trial design. Corewell Health partnered with VUGENE to analyze multi-omics datasets, helping to distinguish important biological signals to reveal disease-relevant biomarkers and mechanisms.
Measuring epigenetic age with Epigenetic Clock Development Foundation
Epigenetic Clock Development Foundation is a Los Angeles-based nonprofit organization that develops tests to estimate biological age from DNA methylation data, offering insights into long-term health outcomes and disease risk. These tests are widely used in clinical research to assess how interventions influence aging before and after treatment. However, converting raw methylation data into reliable biological age measurements requires significant computational processing and scientific expertise.
Epigenetic Clock Development Foundation called upon VUGENE to automate and streamline its data analyses, enabling thousands of studies while also uncovering new patterns that have contributed to the development of novel epigenetic age predictors.
Engineering new gene therapy vectors with rAAVen Therapeutics
Adeno-associated viral vectors (AAVs) are non-pathogenic viruses used to deliver therapeutic genes into disease-causing cells, with applications ranging from vision loss to neurological and genetic disorders. Swedish biotech rAAVen Therapeutics is working to expand and optimize AAV-based therapies by engineering viral vectors that can more effectively target tissues such as the brain, heart, and muscle. This involves screening millions of modified viral candidates, generating extremely large and complex datasets that are difficult to interpret using conventional methods.
rAAVen Therapeutics worked with VUGENE to develop tools that can standardize data screening and help identify viral sequences most likely to achieve the desired therapeutic outcomes, helping to get new therapies to patients as quickly as possible.
Cover photo credits: sripfoto / Adobe Stock
